GENERAL
Biocon Biologics Secures Japan Govt Approval For Pegfilgrastim Biosimilar
Biocon Biologics Ltd, a wholly owned subsidiary of Biocon Ltd., has received marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, strengthening the company’s biosimilars portfolio in the Japanese market. The product is a biosimilar to Neulasta, a pegfilgrastim-based medicine used to reduce the risk of infection associated with […]
CW Bureau
·
Aug 25, 2026
GENERAL
Piramal Pharma Acquires Additional 40.67% Stake In Yapan Bio For ₹76 Cr
Piramal Pharma Ltd has completed the acquisition of an additional 40.67% stake in Yapan Bio Pvt Ltd for ₹76 crore, taking its total holding in the Hyderabad-based company to 74%. With the completion of the transaction on August 18, Yapan Bio has become a subsidiary of Piramal Pharma. The company is a contract development and […]
CW Bureau
·
Aug 19, 2026
GENERAL
Amneal Pharma Completes Kashiv Bio Buy, Strengthens Biosimilars Platform
Amneal Pharmaceuticals Inc. has completed its acquisition of Kashiv BioSciences LLC, creating a fully integrated global biosimilars platform with capabilities spanning research, development, manufacturing and commercialisation. The acquisition brings together Kashiv’s biologics research, development and manufacturing capabilities with Amneal’s commercial scale, positioning biosimilars as a major long-term growth pillar for the company’s affordable medicines business. […]
CW Bureau
·
Aug 11, 2026
GENERAL
Kwality Pharma Ups FY27 Guidance, Targets ₹1,000 Cr Revenue By FY29
Kwality Pharmaceutical Ltd, which has doubled its turnover to ₹500 crore in three years, has raised its FY27 revenue guidance to over ₹700 crore from ₹650 crore and is targeting more than ₹1,000 crore by FY29. “Over the longer term, we continue to work toward doubling revenue over the next three years, with a goal […]
CW Bureau
·
Aug 10, 2026
GENERAL
Aurobindo Pharma Bets On Specialty Drugs, Biosimilars For Next Expansion
Aurobindo Pharma Ltd is doubling down on high-value specialty medicines, biosimilars and complex formulations while strengthening its manufacturing footprint and supply chain resilience as it charts its next phase of global growth. In his message to shareholders in the company’s Annual Report 2026, Vice Chairman & Managing Director K. Nithyananda Reddy said the company will […]
CW Bureau
·
Aug 4, 2026
GENERAL
Shilpa Biologicals Commissions ADC Drug Substance Manufacturing Unit
Shilpa Biologicals Ltd, a material subsidiary of Shilpa Medicare Ltd, has commissioned a Good Manufacturing Practice (GMP)-compliant Antibody-Drug Conjugate (ADC) manufacturing facility designed to meet global regulatory standards. The facility is fully operational, with GMP qualification protocols currently underway, paving the way for commercial-scale operations. Integrated ADC capabilities With the commissioning of the facility, Shilpa […]
CW Bureau
·
Jun 24, 2026
GENERAL
Lupin Secures USFDA Approval For Ranibizumab Biosimilar Ranluspec
Global pharmaceutical major Lupin has received approval from the US Food and Drug Administration (FDA) for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis, marking a significant milestone in the company’s expanding biosimilars portfolio. The approval makes Ranluspec the only interchangeable ranibizumab biosimilar in the United States available in both vial and pre-filled syringe (PFS) presentations. […]
CW Bureau
·
Jun 5, 2026
